Navigation Links
Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress
Date:3/15/2008

mptoms of AD. During the study, the NPI was assessed at the beginning of the study and at weeks 12, 26, 39 and 52. Results showed that Dimebon-treated patients were significantly improved on the NPI total score compared with placebo-treated patients after six months (p=0.01) and one year of treatment (p=0.04). Dimebon treatment resulted in improvement over placebo on 8 of the 12 individual NPI subdomains.

Dimebon Reduced Caregiver Distress

Importantly, the behavioral improvements from Dimebon treatment resulted in a significant decrease in caregiver distress at 6 months (p=0.004) and at one year (p=0.04), compared to the distress of placebo patients' caregivers.

"Alzheimer's disease is a truly devastating disease, robbing patients of their mind and frequently causing significant behavioral problems, which dramatically impact the caregiver," said Lynn Seely, M.D., chief medical officer of Medivation. "There is a tremendous need for new drugs to treat this aspect of the disease, and we believe that Dimebon could provide an important new treatment option."

Dimebon Showed Statistically Significant Benefit Versus Placebo on All Key Efficacy Endpoints

Medivation previously announced efficacy and safety results from the pivotal, 12-month, double-blind, placebo-controlled trial of Dimebon in 183 patients with mild-to-moderate AD. Dimebon demonstrated statistically significant benefit versus placebo on all five efficacy endpoints at both six and 12 months. These endpoints spanned all of the most frequently studied aspects of Alzheimer's disease: cognition and memory, overall clinical function, activities of daily living and behavioral problems. Importantly, on every endpoint studied, the benefits of Dimebon over placebo at one year were stable or greater when compared to benefits at six months. No marketed drug for the treatment of Alzheimer's disease has shown this level of efficacy in published trials. Dimebon was well tolerated throughou
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
2. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
3. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
4. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
5. New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis
6. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
7. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
11. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... 29, 2007-Preliminary results from,the immunotherapeutic cancer study at ... profile for SBG. Furthermore,encouraging responses on cancer development ... treated with SBG in,combination with the monoclonal antibody ... described in the company's report for,the 1st quarter ...
... , * Presentation of efficacy trends from ongoing ... by ESMO for presentation in,press conference , MARTINSRIED, ... Prime Standard: MDG) announces that a case,report from ... will be presented in a press conference held ...
Cached Medicine Technology:Biotec Pharmacon Announces Preliminary Results from the,Sloan-Kettering Clinical Study 2Biotec Pharmacon Announces Preliminary Results from the,Sloan-Kettering Clinical Study 3European Society for Medical Oncology (ESMO) Presents Data from the,Clinical Trial of MediGene's Cancer-Killing Virus in Press,Conference 2
(Date:7/10/2014)... announcement that the "Mississippi Baby," believed to have been ... have detectable levels of the virus, the Elizabeth Glaser ... but remains hopeful that the scientific breakthrough that allowed ... than two years will continue to help researchers understand ... , "Although we had high hopes that the ...
(Date:7/10/2014)... on aggression, who research issues ranging from child abuse ... Meeting of the International Society for Research on Aggression ... Georgia State University is hosting the prestigious world meeting, ... , "We are excited to be bringing together leading ... help produce fresh ideas about the causes, consequences and ...
(Date:7/10/2014)... the amount of alcoholic beverages consumed, even for ... reduced risk of coronary heart disease, lower body ... a new multi-center study published in The ... of Medicine at the University of Pennsylvania. The ... suggest that consuming light-to-moderate amounts of alcohol (0.6-0.8 ...
(Date:7/10/2014)... known as the "Mississippi baby" an infant seemingly cured ... a prolonged remission of HIV infection in The New ... of HIV after more than two years of not taking ... HIV specialist and researchers involved in the case. ... this young child, the medical staff involved in the child,s ...
(Date:7/10/2014)... students looking to bump up their grade point averages ... time in a library or study hall, but in ... that students who were members of the recreational sports ... and sophomore years had higher GPAs than those who ... with memberships stayed in school longer. An increase of ...
Breaking Medicine News(10 mins):Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:New study shows drinking alcohol provides no heart health benefit 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3Health News:Want a higher GPA in college? Join a gym 2
... Oct. 2-6 microTAS 2011 conference, the premier international ... detection technologies for life science and chemistry, University ... method for separating and safely collecting concentrated volumes ... results resolve the critical technical challenge of isolating ...
... , Oxaliplatin, a platinum-based anticancer drug that,s made enormous ... cause nerve damage that may be permanent and worsens ... described by Johns Hopkins researchers in the September issue ... believed to be the first effort to track oxaliplatin-based ...
... Just like extremely premature babies, infants born between 33 and ... 8 to 9, but in these moderately premature children, lung ... shows. "There has been a lot of research demonstrating ... the lung function of children, but limited data on the ...
... The prescribed use of stimulant medications to treat attention ... 1996 to 2008, according to a study conducted by ... for Healthcare Research and Quality (AHRQ). The study was ... the American Journal of Psychiatry. ADHD ...
... Neglected Tropical Diseases will publish an article emphasizing ... Central Asia on Tuesday, Sept. 27th. According to the ... Vaccine Institute, and Dr. Ken Alibek of Nazarbayev University ... a post-Soviet economic breakdown that may have contributed to ...
... , TUESDAY, Sept. 27 (HealthDay News) -- Many children ... the going gets slow, fiber seems to beat all ... A review of nine studies with 640 children ... no known physical cause, found that fiber supplements were ...
Cached Medicine News:Health News:New UC research promises better collection of prostate cancer cells 2Health News:New UC research promises better collection of prostate cancer cells 3Health News:Popular colorectal cancer drug may cause permanent nerve damage 2Health News:Lung Function of Late Preemies May Improve With Age 2Health News:Prescribed stimulant use for ADHD continues to rise steadily 2Health News:Prescribed stimulant use for ADHD continues to rise steadily 3Health News:Central Asia's hidden burden of neglected tropical diseases 2Health News:Fiber Beats Other Remedies for Constipated Kids, Study Says 2Health News:Fiber Beats Other Remedies for Constipated Kids, Study Says 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: